منابع مشابه
Generalized Vaccinia 2 Days after Smallpox Revaccination
To the Editor: Hospital and public health personnel are currently receiving smallpox vaccination in a national effort to increase preparedness for a possible deliberate release of smallpox (1). Generalized vaccinia (GV) is a typically self-limited adverse event following vaccination (incidence 23.4–238.2 cases per million primary vaccinees and 1.2–10.8 cases per million revaccinees) (2,3). We r...
متن کاملChimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.
Chimpanzee Fabs against the B5 envelope glycoprotein of vaccinia virus were isolated and converted into complete mAbs with human gamma 1 heavy chain constant regions. The two mAbs (8AH8AL and 8AH7AL) displayed high binding affinities to B5 (Kd of 0.2 and 0.7 nM). The mAb 8AH8AL inhibited the spread of vaccinia virus as well as variola virus (the causative agent of smallpox) in vitro, protected ...
متن کاملPersistence of vaccinia at the site of smallpox vaccination.
Persistence of vaccinia at vaccination sites may help determine the risk associated with secondary transmission. Culture, PCR, and antigen detection were performed on serial vaccination site swab specimens. On day 21 after vaccination, 37% of volunteers were culture positive, most of whom had received vaccine for the first time. Vaccinia is detectable at least through day 21 after vaccination.
متن کاملSmallpox vaccination of eczema patients with attenuated live vaccinia virus.
Friends of Grover Powers. The late Daniel Darrow, a long-time and dis. tinguished member of your faculty, in 1946, on dedicating his first 76 sci. entific papers in a bound volume to Grover Powers, inscribed it as follows: "To Grover F. Powers, whose faith in people made this work possible." Faith in people is perhaps the best way to characterize Grover Powers' basic attitude in life and this f...
متن کاملHighly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Modified vaccinia virus Ankara (MVA), developed >30 years ago as a highly attenuated candidate smallpox vaccine, was recloned from a 1974 passage and evaluated for safety and immunogenicity. Replication of MVA is impaired in most mammalian cells, and we found that mice with severe combined immunodeficiency disease remained healthy when inoculated with MVA at 1,000 times the lethal dose of vacci...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Boston Medical and Surgical Journal
سال: 1855
ISSN: 0096-6762,1533-4406
DOI: 10.1056/nejm185505310521705